Cognitive deficit in schizophrenia and its neurochemical basis

British Journal of Psychiatry

Volumn 174, Issue FEB. SUPPL. 37, 1999, Pages 16-18

  Breier, Alan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; GLUTAMIC ACID; HALOPERIDOL; N METHYLASPARTIC ACID; NEUROLEPTIC AGENT; PIRENZEPINE;

BRAIN METABOLISM; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; NEUROTRANSMISSION; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COGNITION DISORDERS; GLUTAMIC ACID; HALOPERIDOL; HUMANS; N-METHYLASPARTATE; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032988186     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000293604     Document Type: Review

References (20)

1. Bakshi, V. P. & Geyer, M. A. (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology, 122, 198-201.
2. Breier, A., Schreiber, J. L., Dyer, J., et al (1991) National Institute of Mental Hearth longitudinal study of chronic schizophrenia: prognosis and prediction of outcome. Archives of General Psychiatry, 48, 239-246.
3. _, Buchanan, R.W., Kirkpatrick, B., et al (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20-26.
4. _, Su, T.-P., Saunders, R., et at (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America, 94, 2569-2574.
5. _, Adler, C. M., Weisenfeld, N. L., et al (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse, 29, 142-147.
6. Green, M. F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
7. _, Marshall, B. D. J., Wirshing, W. C., et al (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, 154, 799-804.
8. Hagger, C., Buckley, P., Kenny, J. T., et al (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702-712.
9. Hoff, A. L., Faustman, W. O., Wieneke, M., et al (1996) The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology, 15, 361-369.
10. Krystal, J. H., Karper, L. P., Seibyl, J. P., et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199-214.
11. Lahti, A. C., Koffel, B., LaPorte, D., et al (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13, 9-19.
12. Malhotra, A. K., Adler, C. M., Kennison, S. D., et al (1997a) Clozapine blunts NMDA antagonist-induced psychosis: a study with ketamine. Biological Psychiatry, 41, 664-668.
13. _, Pinals, D. A., Adler, C. M., et al (1997b) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics, implications for NMDA receptor function. Neuropsychopharmacology, 17, 141-150.
14. Park, S., Holzman, P. S. & Goldman-Rakic, P. S. (1995) Spatial working memory deficits in the relatives of schizophrenic patients. Archives of General Psychiatry, 52, 821-828.
15. Purdon, S. E., Jones, B. D.W., Chouinard, G., et al (1998) Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Schizophrenia Research, 29, 152-153.
16. Rupp, A. & Keith, S. J. (1993) The costs of schizophrenia: assessing the burden. Psychiatric Clinics of North America, 16, 413-423.
17. Saykin, A. J., Shtasel, D. L., Gur, R. E., et al (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry, 51, 124-131.
18. Siegel, C., Waldo, M., Mizner, G., et al (1994) Deficits in sensory gating in schizophrenic patients and their relatives. Archives of General Psychiatry, 41, 607-612.
19. Waldo, M. C., Carey, G., Myles-Worsley, M., et al (1991) Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Research, 39, 257-268.
20. _, Cawthra, E., Adler, L. E., et al (1994) Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophrenia Research, 12, 93-106.